Invivyd (IVVD) Other Non-Current Liabilities (2021 - 2023)

Invivyd (IVVD) posted Other Non-Current Liabilities of $700000.0 for Q4 2023, little changed on a QoQ basis from $700000.0 in Q3 2023.

Invivyd (IVVD) Other Non-Current Liabilities (2021 - 2023) Analysis & Trends

Invivyd's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $700000.0 for Q4 2023.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $700000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $700000.0 (changed N/A YoY) and the FY2023 annual result came in at $700000.0, changed N/A from the prior year.
Other Non-Current Liabilities was $700000.0 for Q4 2023 at Invivyd, roughly flat from $700000.0 in the prior quarter.
Across five years, Other Non-Current Liabilities topped out at $700000.0 in Q3 2023 and bottomed at $6000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Invivyd	104.07 Mn	-122.62 Mn	16.07 Mn

Download Data